1) Important Levels
Strong base around 1635–1650
Intermediate support near 1840–1850
Major resistance zone at 2030 (supply zone / overhead resistance)
2) Business
Mid-sized pharmaceutical company with strong presence in branded generics, domestic formulations, and steady export exposure. Known for consistent operational performance.
3) Earnings
Stable earnings profile with improving margins, controlled debt, and consistent cash generation. No major balance sheet stress visible.
4) Verdict
Structure remains bullish within an ascending channel. Price holding above key supports indicates strength. A sustained move beyond the upper supply zone can open further upside over time.